Peptide Raw Powder: Manufacturing and Quality Records

From sequence to isolated powder

1. Resin loading: the C-terminal amino acid is attached to a solid support.
2. Deprotection and coupling: protecting groups are removed and amino acids are added in repeated cycles.
3. Cleavage: the chain is released from the resin and side-chain protecting groups are removed.
4. Crude isolation: the product mixture contains target peptide plus process- and sequence-related impurities.
5. Purification: preparative chromatography separates fractions under a defined method.
6. Concentration and lyophilization: solvent is removed to produce an isolated powder for characterization.

Longer or chemically difficult sequences can increase incomplete coupling, aggregation, oxidation, deamidation, deletion sequences and other side products. The correct test panel depends on the molecule and process.

The quality questions are separate

On phone, swipe sideways to compare all columns.

How to read HPLC purity

Analytical HPLC separates components under a defined column, mobile phase, gradient, temperature and detection method. The reported area percentage is the target peak's signal relative to other detected peaks. A result is therefore method-specific: changing the detector wavelength or separation conditions can change what is visible and how well co-eluting impurities are resolved.

A value such as 99% HPLC purity does not mean that 99% of the powder mass is peptide. Water, counterions, residual solvents and components with different detector response can affect mass without appearing as equivalent peak area. Any separate content or assay result must be read on its own terms.

Why orthogonal testing matters

A chromatographic peak can be highly pure and still be the wrong molecule. Mass spectrometry tests molecular mass; amino-acid analysis, peptide mapping or another suitable method can test a different characteristic. Agreement across independent properties is stronger evidence than repeating the same type of measurement.

For a field-by-field example, use the peptide COA guide. The COA archive is a fixed record of named historical batches, not a catalogue or availability surface.

What a Certificate of Analysis cannot prove

• that untested material or a later batch matches the tested sample;
• sterility when no sterility method is named;
• clinical safety, efficacy or suitability;
• stability beyond the study conditions and period;
• medicine approval, lawful import or a general research-use exemption.

Regulatory status is compound-, use- and jurisdiction-specific. In the UAE, public guidance regulates medicines and controlled medicines and describes permit requirements for some imports; it does not establish a blanket peptide exception. See the UAE regulatory guide.

FDA PCAC votes July 23–24, 2026: six peptides recommended

The FDA Pharmacy Compounding Advisory Committee concluded its July 23–24, 2026 meeting by voting to recommend six of the seven candidate peptides for the 503A Bulks List, in free base and acetate forms where applicable: BPC-157 (8–6, one abstention; evaluated use: ulcerative colitis), KPV (8–6, one abstention; wound healing and inflammatory conditions), TB-500 (8–6, one abstention; wound healing), MOTS-c (7–5, two abstentions; obesity and osteoporosis), Epitalon (insomnia), and Semax (8–5, one abstention; cerebral ischemia, migraine, trigeminal neuralgia). Emideltide (DSIP) was the only candidate not recommended (6–7, one abstention).

The recommendations are advisory, and FDA’s own scientific review staff opposed inclusion of all seven peptides, so the agency may still depart from the committee. Formal notice-and-comment rulemaking — which commonly takes a year or more — must conclude before any 503A list change takes effect. No compound gained an approved indication, and the votes do not change the research-only status of any research-grade peptide. Sources: FDA meeting page and materials; McDermott Will & Schulte meeting analysis. Full tallies and rulemaking outlook: PCAC explainer.